Compare Gemini Space Station Inc (GEMI) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Johnson & Johnson — how do they compare? Gemini Space Station Inc trades at $4.24 (market cap $512.05M), while Johnson & Johnson trades at $260.94 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 1222.7× Gemini Space Station Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals.
| GEMI | JNJ | |
|---|---|---|
Market Cap | $512.05M | $626.09B |
Sector | Technology | Health |
52-Week High | $32.52 | $267.24 |
52-Week Low | $3.90 | $172.78 |
Enterprise Value | $502.04M | $654.37B |
Volume | — | 6,156,228 |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.085, down 0.61% on the day, with technical indicators showing a bearish trend. The company reported significant losses with a net income margin of -278.9% in 2025 and has missed earnings expectations for three consecutive quarters. Recent developments include a $100 million investment from Winklevoss Capital and the launch of commission-free stock trading as part of its super app strategy.
Despite analyst consensus pointing to upside potential with a $6.33 price target, GEMI faces substantial execution risks amid ongoing securities lawsuits and persistent negative profitability. The stock presents high-risk speculative appeal for investors betting on the company's financial infrastructure transformation, but current fundamentals remain deeply concerning.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
